|

TAS0953/HM06 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Taiho Pharmaceutical Co., Ltd.1

Indications

  • RET-altered Solid Tumors1
  • RET-altered Non Small Cell Lung Cancer1
  • Lung Cancer1
  • Cancer1

Orange, California1 trial

Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Chao Family Comprehensive Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.